# proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

> **NCT05590143** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Amsterdam UMC** · enrollment: 784 (actual)

## Conditions studied

- Acute Kidney Injury
- Cardiac Surgery
- Sodium-Glucose Transporter 2 Inhibitor

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet [Farxiga]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05590143
- **Lead sponsor:** Amsterdam UMC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-09
- **Primary completion:** 2025-05-14
- **Final completion:** 2025-09
- **Target enrollment:** 784 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590143, "proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05590143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*